Article
6m Read
April 08, 2025
COMMUNITY AND GLOBAL HEALTH
Expert Perspective
5m Read
April 01, 2025
COMMUNITY AND GLOBAL HEALTH
Main Menu
-
Solutions
Back
Cepheid’s Solutions
-
Global Access
-
Testing Everywhere
Back
Testing Everywhere
-
Antibiotic Stewardship
-
Customized Testing for Your Institution
-
Knowing MORE Matters
-
-
Insights
Back
Cepheid’s Insights
-
Webinars
Back
Webinars
-
Cepheid RADAR
Back
Cepheid RADAR
-
Support
Back
Support Center
-
Documents & Technical Resources
-
Troubleshooting and How-tos
-
MyCepheid and Order Support
-
Contact Us
Back
Contact Us
-
-
About Us
Back
About Cepheid
-
Mission and History
Back
Mission and History
-
Our Leadership
Back
Our Leadership
-
Events
Back
Events
-
Distributors
Back
Distributors
-
Business Development Opportunities
-
Innovate with Cepheid
-
Meet the Cepheid Bike
-
News
Back
News
-
Careers
Back
Careers
-
The Need
- Each day, close to 4,400 people lose their lives to TB and nearly 30,000 people fall ill with this preventable and curable disease1
- Globally, diagnosis of TB and drug-resistant TB remains a challenge, with a third of people with TB and two-thirds of people with drug-resistant TB not being detected1
- Precise and early detection of TB is needed to improve case management and significantly enhance the prevention of TB transmission2
1 World Health Organization Tuberculosis Report 2023 - https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
2 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB - https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm
2 Centers for Disease Control and Prevention—Guidelines for preventing the transmission of TB - https://www.cdc.gov/mmwr/preview/mmwrhtml/00001897.htm
The Solution
- Xpert MTB/RIF Ultra provides fast and highly accurate detection of Mycobacterium Tuberculosis (MTB) and Rifampicin (RIF) resistance simultaneously from patient samples
- Higher sensitivity, especially in smear-negative TB cases and among HIV-infected patients3
- Simple three-step process with minimal hands-on time and results in ~80 min direct from sample
- Designed to provide highly accurate MTB and Rifampicin detection utilizing multi-target and melt curves technology
3 Aliasgar Esmail, et al, Comparison of Xpert MTB/RIF (G4) and Xpert Ultra, including trace readouts, for the diagnosis of pulmonary tuberculosis in a TB and HIV endemicsetting https://researchonline.lshtm.ac.uk/id/eprint/4661245/1/1-s2.0-S1201971220301442-main.pdf
The Impact
- Early detection of MTB and RIF resistance can support timely clinical decision‑making and appropriate therapy initiations4
- IIncreased access to front‑line testing with Xpert MTB/RIF Ultra as part of active case finding and management can help support control activities5
- Superior sensitivity to smear microscopy enables detection of more MTB‑positive patients, with results available in ~80 minutes to support prompt clinical assessment
4 Charkravorty S, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing - https://journals.asm.org/doi/10.1128/mbio.00812-17
5 Belén Saavedra, et al. Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding - https://erj.ersjournals.com/content/58/6/2100257
5 Belén Saavedra, et al. Performance of Xpert MTB/RIF Ultra for tuberculosis diagnosis in the context of passive and active case finding - https://erj.ersjournals.com/content/58/6/2100257